RBFOX1 and central nervous system cancer: In a temozolomide (TMZ)-insensitive cell line and in a mouse model of TMZ-resistant high-grade gliomas, blocking the FOX1/survivin axis with the protease inhibitor bortezomib resulted in decreased tumor growth with increased apoptotic activity.